Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

UNC Alumni on Pulitzer-Winning Journalism Teams
Three alumni of the Hussman School of Media and Journalism — Brian Cassella ’05, Alex Kormann ’19 and Emmy Martin ’25 — were part of...
Wed May 27, 2026

Eric Church Uses His Guitar To Deliver Powerful Commencement Speech At UNC
UNC-Chapel Hill held its 2026 graduation ceremony, and the commencement address was delivered by North Carolina native and diehard Tar Heel fan Eric Church. And...
Mon May 25, 2026

Carolina Performing Arts Unveils Multi-Day Performance Festival for ‘Campus and Downtown’
May is Mental Health Awareness Month and, in our modern society, many people are struggling with loneliness and finding connection with others. Alison Friedman, the...
Sun May 24, 2026

Play-by-Play Class in UNC’s Journalism School Wraps Up Debut Semester
Listeners of 97.9 The Hill know Matt Krause as the voice of UNC women’s basketball. The most recent season was Krause’s eighth behind the mic...
Sat May 23, 2026